August 26, 2020

Lannett Announces Fiscal 2020 Fourth-Quarter, Full-Year Financial Results

PHILADELPHIA, Aug. 26, 2020 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth…

PHILADELPHIA, Aug. 26, 2020 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. 

“For both the fiscal 2020 full year and fourth quarter, our net sales and profitability exceeded expectations, driven in large part by a strong performance of our base portfolio and 18 and six new product launches during the year and quarter, respectively,” said Tim Crew, chief executive officer of Lannett. “Moreover, during the fourth quarter, we increased our cash position by more than $40 million to approximately $144 million at year end, due to initiatives implemented to improve working capital.  We intend to use a portion of the cash to pay down, in full, our Term A Loans at their maturity in November of this year.

“Thus far in fiscal 2021, we have implemented and nearly completed a restructuring and cost reduction plan that we estimate will lower our expenses by approximately $15 million, annually, and launched four new products, including Levothyroxine Tablets.  Over the course of the coming year, we intend to continue to launch a number of new products and expand our pipeline through in-house development efforts, as well as in-licensing agreements.  We are especially excited and optimistic about recent clinical progress related to a number of drug candidates in our portfolio that have very large addressable markets; we believe these products also have durable value and the potential to be catalysts for significant growth. 

“We have provided guidance for the upcoming year, which includes the expected contribution from a number of new product launches in the coming year and a full year of contribution from the 18 products we launched in fiscal 2020.  Our outlook also reflects recent and anticipated competitive pressure on certain key products, as well as lower operating expenses as a result of our recently announced restructuring and cost reduction plan.”

For the fiscal 2020 fourth quarter on a GAAP basis, net sales were $137.9 million compared with $133.8 million for the fourth quarter of fiscal 2019. Gross profit was $39.6 million, or 29% of net sales, compared with $49.3 million, or 37% of net sales. The company recorded asset impairment charges of $18.8 million compared with $5.9 million in the prior-year fourth quarter. Net loss was $9.7 million, or $0.25 per share, compared with $7.6 million, or $0.20 per share, for the fourth quarter of fiscal 2019.

For the fiscal 2020 fourth quarter reported on a Non-GAAP basis, net sales were $137.9 million compared with $133.8 million for the fourth quarter of fiscal 2019. Adjusted gross profit was $48.9 million, or 35% of net sales, compared with $59.8 million, or 45% of net sales, for the prior-year fourth quarter. Adjusted interest expense decreased to $11.3 million compared with $16.0 million for the fourth quarter of fiscal 2019. Adjusted net income was $13.4 million, or $0.31 per diluted share, compared with $14.7 million, or $0.37 per diluted share, for the fiscal 2019 fourth quarter. Adjusted EBITDA for the fiscal 2020 fourth quarter was $35.2 million.

For the fiscal 2020 full year, on a GAAP basis, net sales were $545.7 million compared with $655.4 million for the fiscal 2019 full year. Gross profit was $165.2 million, or 30% of total net sales, compared with $243.6 million, or 37% of total net sales. The company recorded asset impairment charges of $34.4 million compared with $375.4 million for fiscal 2019. Net loss was $33.4 million, or $0.86 per share, compared with $272.1 million, or $7.20 per diluted share, for fiscal 2019.

For the fiscal 2020 full year reported on a Non-GAAP basis, net sales were $545.7 million compared with $655.4 million for the fiscal 2019 full year. Adjusted gross profit was $204.0 million, or 37% of adjusted net sales, compared with $291.4 million, or 44% of adjusted net sales, for the prior year. Adjusted interest expense significantly declined to $52.5 million from $67.0 million for fiscal 2019. Adjusted net income was $45.6 million, or $1.07 per diluted share, compared with $91.8 million, or $2.35 per diluted share, for the fiscal 2019 full year.

Guidance for Fiscal 2021

Based on its current outlook, the company provided guidance for fiscal year 2021, as follows:


GAAP

Adjusted**

Net sales

$520 million to $545 million

$520 million to $545 million

Gross margin %

Approximately 23% to 25%

Approximately 29% to 31%

R&D expense

$29 million to $32 million

$29 million to $32 million

SG&A expense

$59 million to $62 million

$55 million to $58 million

Restructuring expense

$4 million to $5 million

$ —

Interest and other

$53 million to $54 million

$41 million to $42 million

Effective tax rate

Approximately 34% to 35%

Approximately 21% to 22%

Adjusted EBITDA*

N/A

$100 million to $110 million

Capital expenditures

$15 million to $20 million

$15 million to $20 million

**A reconciliation of Adjusted amounts to most directly comparable GAAP amounts can be found in the attached financial tables.

Conference Call Information and Forward-Looking Statements

Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for its fiscal 2020 fourth quarter ended June 30, 2020. The conference call will be available to interested parties by dialing 800-447-0521 from the U.S. or Canada, or 847-413-3238 from international locations, passcode 49903262. The call will be broadcast via the Internet at www.lannett.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company’s financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

Use of Non-GAAP Financial Measures

This news release contains references to Non-GAAP financial measures, including Adjusted EBITDA, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). Management uses these measures internally for evaluating its operating performance. The Company’s management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor’s overall understanding of the financial results for the Company’s core business. Additionally, it provides a basis for the comparison of the financial results for the Company’s core business between current, past and future periods. The company also believes that including Adjusted EBITDA, as defined in the company’s existing Credit Agreement, is appropriate to provide additional information to investors to demonstrate the company’s ability to comply with financial debt covenants. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP.

Detailed reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included with this release.

Non-GAAP financial measures exclude, among others, the effects of (1) amortization of purchased intangibles and other purchase accounting entries, (2) restructuring expenses, (3) non-cash interest expense, as well as (4) certain other items considered unusual or non-recurring in nature.

*Adjusted EBITDA excludes the same adjustments discussed above, as well as additional adjustments permitted under the company’s existing Credit Agreement.

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications – see financial schedule below for net sales by medical indication. For more information, visit the company’s website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance.  Any such statements, including, but not limited to, successfully commercializing recently introduced products, launching and successfully commercializing additional products in fiscal 2021, achieving cost savings from the recently announced restructuring and cost savings plan, the potential material impact of COVID-19 on future financial results, and achieving the financial metrics stated in the company’s guidance for fiscal 2021, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, including acquired products, and Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time.  These forward-looking statements represent the company’s judgment as of the date of this news release.  The company disclaims any intent or obligation to update these forward-looking statements.

 

Contact:

Robert Jaffe


Robert Jaffe Co., LLC


(424) 288-4098

 

 

 



FINANCIAL SCHEDULES FOLLOW



LANNETT COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)




(Unaudited)





June 30, 2020


June 30, 2019






ASSETS




Current assets:




Cash and cash equivalents

$         144,329


$       140,249

Accounts receivable, net

125,688


164,752

Inventories

142,867


143,971

Income taxes receivable

14,419


Assets held for sale

2,678


9,671

Other current assets

13,227


13,606

Total current assets

443,208


472,249

Property, plant and equipment, net

179,518


186,670

Intangible assets, net

374,735


411,229

Operating lease right-of-use asset 

9,343


Deferred tax assets

117,890


109,305

Other assets

11,861


7,960

TOTAL ASSETS

$      1,136,555


$    1,187,413











LIABILITIES




Current liabilities:




Accounts payable

$           32,535


$         13,493

Accrued expenses

14,962


5,805

Accrued payroll and payroll-related expenses

16,304


19,924

Rebates payable

38,175


46,175

Royalties payable

20,863


16,215

Restructuring liability

27


2,315

Income taxes payable


2,198

Current operating lease liabilities

1,097


Short-term borrowings and current portion of long-term debt

88,189


66,845

Other current liabilities

2,713


3,652

Total current liabilities

214,865


176,622

Long-term debt, net

592,940


662,203

Long-term operating lease liabilities

9,844


Other liabilities

16,010


14,547

TOTAL LIABILITIES

833,659


853,372






STOCKHOLDERS’ EQUITY




Common stock ($0.001 par value, 100,000,000 shares authorized; 39,963,127 and 38,969,518 shares issued; 38,798,787 and 38,010,714 shares outstanding at June 30, 2020 and June 30, 2019, respectively)

40


39

Additional paid-in capital

321,164


317,023

Retained earnings

(1,291)


32,075

Accumulated other comprehensive loss

(627)


(615)

Treasury stock (1,164,340 and 958,804 shares at June 30, 2020 and June 30, 2019, respectively)

(16,390)


(14,481)

Total stockholders’ equity

302,896


334,041

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 

$      1,136,555


$    1,187,413










LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In thousands, except share and per share data)










Three months ended 


Twelve months ended 


June 30,


June 30,


2020


2019


2020


2019









Net sales

$       137,920


$          133,841


$       545,744


$          655,407

Cost of sales 

89,809


76,589


348,508


379,601

Amortization of intangibles

8,519


7,910


32,016


32,196

Gross profit

39,592


49,342


165,220


243,610

Operating expenses:








Research and development expenses

6,691


9,436


29,978


38,807

Selling, general and administrative expenses

18,591


22,214


79,467


87,648

Restructuring expenses


2,408


1,771


4,095

Asset impairment charges

18,841


5,882


34,448


375,381

Total operating expenses

44,123


39,940


145,664


505,931

Operating income (loss)

(4,531)


9,402


19,556


(262,321)

Other income (loss):








Loss on extinguishment of debt


(35)


(2,145)


(448)

Investment income

94


1,306


1,646


3,166

Interest expense

(14,682)


(20,194)


(66,845)


(84,624)

Other

(659)


(609)


(840)


(2,018)

Total other loss

(15,247)


(19,532)


(68,184)


(83,924)

Loss before income tax

(19,778)


(10,130)


(48,628)


(346,245)

Income tax benefit

(10,077)


(2,544)


(15,262)


(74,138)

Net loss 

$          (9,701)


$            (7,586)


$        (33,366)


$        (272,107)









Loss per common share:








     Basic

$             (0.25)


$              (0.20)


$             (0.86)


$              (7.20)

     Diluted (1) 

$             (0.25)


$              (0.20)


$             (0.86)


$              (7.20)









Weighted average common shares outstanding:








     Basic

38,752,080


37,932,509


38,592,618


37,779,812

     Diluted (1) 

38,752,080


37,932,509


38,592,618


37,779,812

(1) Effective with the 4.5% Senior Convertible Note issued on September 27, 2019, the diluted earnings per share was calculated based on the “if-converted” method.





LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)
















Three months ended June 30, 2020


Net sales

Cost of sales

Amortization of intangibles

Gross Profit

Gross Margin %

R&D expenses

SG&A expenses

Asset impairment charges

Operating income

(loss)

Other income (loss)

Income

(loss)

before

income tax

Income

tax

expense

(benefit)

Net

income

(loss)

Diluted earnings (loss) per share (i)

GAAP Reported

$137,920

$     89,809

$        8,519

$ 39,592

29%

$     6,691

$      18,591

$             18,841

$         (4,531)

$ (15,247)

$   (19,778)

$ (10,077)

$    (9,701)

$         (0.25)

Adjustments:















Amortization of intangibles (a)

(8,519)

8,519


8,519

8,519

8,519


Cody API business (b)

158

(158)


(66)

(95)

3

3

3


Depreciation on capitalized software costs (c)


(1,058)

1,058

1,058

1,058


Decommissioning of Philadelphia sites (d)

(419)

419


419

419

419


Asset impairment charges (e)


(18,841)

18,841

18,841

18,841


Non-cash interest (f)


3,335

3,335

3,335


Other (g)

(508)

508


(64)

(1,817)

2,389

2,389

2,389


Tax adjustments (h)


11,436

(11,436)

















Non-GAAP Adjusted

$  137,920

$       89,040

$              –

$   48,880

35%

$       6,561

$        15,621

$                     –

$          26,698

$   (11,912)

$      14,786

$    1,359

$     13,427

$            0.31
















(a)

To exclude amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc.



(b)

To exclude the operating results of the ceased Cody API business

(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition

(d)

To exclude the costs associated with the decommissioning and shutdown of the Philadelphia manufacturing and distribution sites

(e)

To exclude asset impairment charges primarily related to the abandonment of several pipeline products within the KUPI IPR&D and Silarx IPR&D asset portfolios

(f)

To exclude non-cash interest expense associated with debt issuance costs

(g)

To exclude costs primarily related to separation costs related to the Company’s cost reduction plan, COVID-19 special recognition payments, as well as costs previously incurred as part of the Company’s refinancing efforts

(h)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates

(i)

The weighted average share number for the three months ended June 30, 2020 is 38,752,080 for GAAP and 46,111,366 for non-GAAP earnings (loss) per share calculations








LANNETT COMPANY, INC.


RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)


(In thousands, except percentages, share and per share data)



















Three months ended June 30, 2019



Net sales

Cost of sales

Amortization

of intangibles

Gross Profit

Gross

Margin %

R&D expense

SG&A

expense

Restructuring

expenses

Asset

impairment

charges

Operating

income

Other income

(loss)

Income (loss)

before

income tax

Income tax

expense

(benefit)

Net income

(loss)

Diluted

earnings

(loss) per

share (m)







GAAP Reported

$    133,841

$      76,589

$        7,910

$      49,342

37%

$        9,436

$      22,214

$        2,408

5,882

$        9,402

$     (19,532)

$     (10,130)

$       (2,544)

$       (7,586)

$         (0.20)


Adjustments:

















Amortization of intangibles (a)

(7,910)

7,910


7,910

7,910

7,910



Cody API business (b)

(2,233)

2,233


(760)

(1,394)


4,387

4,387

4,387



Depreciation on capitalized software costs (c)


(1,058)

1,058

1,058

1,058



Legal and financial advisory costs (d)


(237)

237

237

237



Decommissioning of Philadelphia sites (e)

(89)

89


(64)

153

153

153



Restructuring expenses (f)


(2,408)

2,408

2,408

2,408



Indemnification asset write-off (g)


(2,284)

2,284

2,284

2,284



Asset impairment charges (h)


(5,882)

5,882

5,882

5,882



Non-cash interest (i)


4,201

4,201

4,201



Loss on extinguishment of debt (j)


34

34

34



Other (k)

(209)

209


(195)

404

(242)

162

162



Tax adjustments (l)


6,460

(6,460)




















Non-GAAP Adjusted

$      133,841

$        74,058

$              –

$        59,783

45%

$          8,612

$        17,046

$              –

$              –

$        34,125

$       (15,539)

$        18,586

$          3,916

$        14,670

$           0.37



















(a)

To exclude amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc.


(b)

To exclude the operating results of the ceased Cody API business

(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition

(d)

To exclude legal and financial advisory costs primarily related to exploring and evaluating debt and capital structure alternatives

(e)

To exclude the costs associated with the decommissioning and shutdown of the Philadelphia manufacturing and distribution sites

(f)

To exclude expenses associated with the Cody API Restructuring Plan

(g)

To exclude the write-off of an indemnification asset related to the KUPI acquisition

(h)

To exclude asset impairment charges primarily associated with the Cody API assets as well as obsolete equipment and computer software related to the consolidation of manufacturing functions

(i)

To exclude non-cash interest expense associated with debt issuance costs

(j)

To exclude the loss on extinguishment of debt related to repurchases of Term Loans

(k)

To primarily exclude accrued separation costs related to the Company’s Chief Financial Officer

(l)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates

(m)

The weighted average share number for the three months ended June 30, 2019 is 37,932,509 for GAAP and 39,345,258 for non-GAAP earnings (loss) per share calculations







LANNETT COMPANY, INC.


RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)


(In thousands, except percentages, share and per share data)



















Twelve months ended June 30, 2020



Net sales

Cost of sales

Amortization

of intangibles

Gross

Profit

Gross

Margin

%

R&D

expenses

SG&A

expenses

Restructuring

expenses

Asset

impairment

charges

Operating

income 

Other

income

(loss)

Income

(loss) before

income tax

Income tax

expense

(benefit)

Net income

(loss)

Diluted

e
arnings

(loss) per

share (l)








GAAP Reported

$  545,744

$   348,508

$      32,016

$  165,220

30%

$   29,978

$     79,467

$         1,771

$     34,448

$    19,556

$   (68,184)

$    (48,628)

$   (15,262)

$       (33,366)

$    (0.86)


Adjustments:

















Amortization of intangibles (a)

(32,016)

32,016


32,016

32,016

32,016



Cody API business (b)

(2,752)

2,752


(617)

(528)

3,897

3,897

3,897



Depreciation on capitalized software costs (c)


(4,233)

4,233

4,233

4,233



Decommissioning of Philadelphia sites (d)

(1,903)

1,903



1,903

1,903

1,903



Branded prescription drug fee (e)


(2,957)

2,957

2,957

2,957



Restructuring expenses (f)


(1,771)

1,771

1,771

1,771



Asset impairment charges (g)


(34,448)

34,448

34,448

34,448



Non-cash interest (h)


14,336

14,336

14,336



Loss on extinguishment of debt (i)


2,145

2,145

2,145



Other (j)

(2,094)

2,094


(94)

(4,395)

6,583

21

6,604

6,604



Tax adjustments (k)


25,378

(25,378)




















Non-GAAP Adjusted

$    545,744

$     341,759

$              –

$    203,985

37%

$     29,267

$       67,354

$               –

$             –

$    107,364

$     (51,682)

$       55,682

$      10,116

$          45,566

$      1.07



















(a)

To exclude amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc.

(b)

To exclude the operating results of the ceased Cody API business

(c)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition

(d)

To exclude the costs associated with the decommissioning and shutdown of the Philadelphia manufacturing and distribution sites

(e)

To exclude the federally mandated branded prescription drug fee related to Levothyroxine, a product the Company no longer sells

(f)

To exclude expenses associated with the Cody API Restructuring Plan

(g)

To exclude asset impairment charges primarily associated with an agreement to distribute Methylphenidate AB and related to the abandonment of several pipeline products within the KUPI IPR&D and Silarx IPR&D asset portfolios

(h)

To exclude non-cash interest expense associated with debt issuance costs

(i)

To exclude the loss on extinguishment of debt primarily related to the partial repayment of the outstanding Term Loan A balance

(j)

To primarily exclude accrued separation costs related to the Company’s former Chief Financial Officer and the Company’s cost reduction plan, as well as COVID-19 special recognition payments, legal settlements and costs previously incurred as part of the Company’s refinancing efforts, partially offset by gains on sales of assets previously held for sale

(k)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates

(l)

The weighted average share number for the twelve months ended June 30, 2020 is 38,592,618 for GAAP and 44,677,463 for the non-GAAP earnings (loss) per share calculations







LANNETT COMPANY, INC.


RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION


(In thousands, except percentages, share and per share data)



















Twelve months ended June 30, 2019



Net sales

Cost of

sales

Amortization

of intangibles

Gross Profit

Gross

Margin %

R&D

expense

SG&A

expense

Restructuring

expenses

Asset impairment

charges

Operating

income

Other

income

(loss)

Income

(loss) before

income tax

Income

tax

expense

(benefit)

Net

income

Diluted

earnings (loss)

per share (n)








GAAP Reported

$ 655,407

$ 379,601

$      32,196

$   243,610

37%

$  38,807

$   87,648

$         4,095

$           375,381

$ (262,321)

$ (83,924)

$ (346,245)

$ (74,138)

$(272,107)

$            (7.20)


Adjustments:

















Depreciation of fixed assets step-up (a)

(2,459)

2,459


2,459

2,459

2,459



Amortization of intangibles (b)

(32,196)

32,196


32,196

32,196

32,196



Cody API business (c)

(7,061)

7,061


(2,397)

(2,340)

11,798

11,798

11,798



Depreciation on capitalized software costs (d)


(4,233)

4,233

4,233

4,233



Legal and financial advisory costs (e)


(3,626)

3,626

3,626

3,626



Decommissioning of Philadelphia sites (f)

(4,114)

4,114


(64)

4,178

4,178

4,178



Restructuring expenses (g)


(4,095)

4,095

4,095

4,095



Asset impairment charges (h)


(375,381)

375,381

375,381

375,381



Indemnification asset write-off (i)


(3,094)

3,094

3,094

3,094



Non-cash interest (j)


17,649

17,649

17,649



Loss on extinguishment of debt (k)


448

448

448



Other (l)

(1,960)

1,960


(210)

(3,173)

5,343

977

6,320

6,320



Tax adjustments (m)


101,526

(101,526)




















Non-GAAP Adjusted

$   655,407

$   364,007

$              –

$     291,400

44%

$    36,136

$    71,182

$               –

$                     –

$     184,082

$   (64,850)

$     119,232

$   27,388

$     91,844

$              2.35



















(a)

To exclude depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. (“KUPI”)


(b)

To exclude amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc.


(c)

To exclude the operating results of the ceased Cody API business

(d)

To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition

(e)

To exclude legal and financial advisory costs primarily related to exploring and evaluating debt and capital structure alternatives, including the December 2018 amendment to our Credit Agreement

(f)

To exclude the costs associated with the decommissioning and shutdown of the Philadelphia manufacturing and distribution sites

(g)

To exclude expenses associated with the 2016 Restructuring Plan, the Cody Restructuring Plan as well as the Cody API Restructuring Plan

(h)

To exclude asset impairment charges primarily related to goodwill and other long-lived assets

(i)

To exclude the write-off of indemnification assets related to the KUPI acquisition

(j)

To exclude non-cash interest expense associated with debt issuance costs

(k)

To exclude the loss on extinguishment of debt related to repurchases of Term Loans

(l)

To primarily exclude separation costs related to the Company’s cost reduction plan, a special recognition incentive payment as well as a litigation settlement

(m)

To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates

(n)

The weighted average share number for the twelve months ended June 30, 2019 is 37,779,812 for GAAP and 39,135,719 for the non-GAAP earnings (loss) per share calculations




LANNETT COMPANY, INC.

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (UNAUDITED)

($ in thousands)






Three months ended 



June 30, 2020




Net loss


$                 (9,701)




Interest expense


14,682

Depreciation and amortization


14,923

Income tax benefit


(10,077)

EBITDA


9,827




Share-based compensation


1,880

Inventory write-down


1,855

Asset impairment charges


18,841

Investment income


(94)

Other non-operating loss


659

Restructuring payments


(142)

Decommissioning of Philadelphia sites (a)


419

Other(b)


1,966

Adjusted EBITDA (Non-GAAP)


$                35,211



(a)

To exclude the costs associated with the decommissioning and shutdown of the Philadelphia manufacturing and distribution sites

(b)

To exclude costs primarily related to separation costs related to the Company’s cost reduction plan, COVID-19 special recognition payments, costs previously incurred as part of the Company’s refinancing efforts and the operating results of the ceased Cody API business




LANNETT COMPANY, INC.

RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

($ in millions)







Fiscal Year 2021 Guidance








Non-GAAP




GAAP


Adjustments


Adjusted










Net sales


 $520 – $545 



 $520 – $545 


Gross margin percentage


approx. 23.0% to 25.0%


6%

 (a) 

approx. 29% to 31%


R&D expense


 $29 – $32 



 $29 – $32 


SG&A expense


 $59 – $62 


($4)

 (b) 

 $55 – $58 


Restructuring expense


 $4 – $5 


 ($4 – $5) 

 (c) 


Interest and other


 $53 – $54 


($12)

 (d) 

 $41 – $42 


Effective tax rate


 approx. 34% to 35% 


(13%)

 (e) 

approx. 21% to 22%


Adjusted EBITDA


 N/A 


 N/A 


 $100 – $110 


Capital expenditures


 $15 – $20 



 $15 – $20 



(a) The adjustment primarily reflects amortization of purchased intangible assets related to the acquisition of Kremers Urban Pharmaceuticals, Inc. (“KUPI”)

(b) The adjustment excludes depreciation on previously capitalized software integration costs associated with the KUPI acquisition

(c) To exclude expenses associated with the 2020 Restructuring Plan

(d) The adjustment primarily reflects non-cash interest expense associated with debt issuance costs

(e) The adjustment reflects the impact of the CARES Act, which allows the Company to carryback the expected taxable loss into a prior fiscal year, where the statutory tax rate was 35%




LANNETT COMPANY, INC.

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (UNAUDITED)

($ in millions)






Fiscal Year 2021 Guidance


Low


High





Net loss

$                 (16.5)


$                 (11.0)





Interest expense

53.0


54.0

Depreciation and amortization

55.0


55.0

Income taxes

(8.5)


(6.0)

EBITDA

83.0


92.0





Share-based compensation

9.0


9.0

Inventory write-down

8.0


9.0

Restructuring expenses

4.0


5.0

Restructuring payments

(4.0)


(5.0)

Adjusted EBITDA (Non-GAAP)

$                 100.0


$                 110.0




LANNETT COMPANY, INC.

NET SALES BY MEDICAL INDICATION










Three months ended


Twelve months ended

($ in thousands)

June 30,


June 30,

Medical Indication

2020


2019


2020


2019

Analgesic

$             1,874


$             2,929


$             8,680


$             8,251

Anti-Psychosis

26,346


27,912


104,934


73,453

Cardiovascular

21,251


31,234


88,576


101,467

Central Nervous System

20,102


21,454


77,256


59,019

Endocrinology


(43)



197,522

Gastrointestinal

17,457


16,005


73,477


63,043

Infectious Disease

21,515


3,692


73,237


16,950

Migraine

11,359


9,458


44,266


41,592

Respiratory/Allergy/Cough/Cold

2,829


2,958


11,576


12,479

Urinary

1,408


1,522


4,225


6,755

Other

7,166


13,859


35,013


51,517

Contract Manufacturing revenue

6,613


2,861


24,504


23,359

   Net Sales

$          137,920


$          133,841


$          545,744


$          655,407

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lannett-announces-fiscal-2020-fourth-quarter-full-year-financial-results-301118666.html

SOURCE Lannett Company, Inc.